Opus Genetics
IRD

Opus Genetics (IRD) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
RBC CapitalMaintainedOutperform$9.00 from $10.00Aug 7, 2026
TD CowenInitiated CoverageBuyJul 29, 2026
BTIGMaintainedBuy$12.00Jul 6, 2026
Chardan CapitalMaintainedBuy$13.00Jul 6, 2026
Chardan CapitalMaintainedBuy$13.00 from $11.00Jun 18, 2026
HC Wainwright & Co.MaintainedBuy$8.00Jun 17, 2026
BTIGMaintainedBuy$12.00Jun 16, 2026
CitizensMaintainedMarket Outperform$11.00Jun 15, 2026
GuggenheimInitiated CoverageBuy$16.00Jun 4, 2026
Leerink PartnersInitiated CoverageOutperform$10.00May 21, 2026
CitizensMaintainedMarket Outperform$11.00 from $12.00May 13, 2026
CitizensInitiated CoverageMarket Outperform$12.00Apr 28, 2026
Cantor FitzgeraldInitiated CoverageOverweight$15.00Mar 30, 2026
OppenheimerInitiated CoverageOutperform$10.00Mar 16, 2026
Chardan CapitalMaintainedBuy$11.00 from $9.00Mar 12, 2026
WedbushMaintainedOutperform$10.00 from $8.00Mar 12, 2026
BTIGMaintainedBuy$12.00 from $7.00Mar 2, 2026
BTIGMaintainedBuy$7.00Jan 28, 2026
BTIGInitiated CoverageBuy$7.00Jan 20, 2026
B. Riley SecuritiesInitiated CoverageBuy$9.00Dec 10, 2025

Frequently asked questions

  • What is the latest analyst rating on IRD?

    On Aug 7, 2026, RBC Capital maintained Opus Genetics at Outperform with a price target of $9.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.